FDA regulatory roundup: two approvals, three rejections & one clinical hold March 6, 2022 Auto Bot BioPharma, biopharma nl, cancer, Clinical Trials, FDA, Gilead Sciences, Johnson & Johnson, Legal, Pharma 0 The FDA approved drugs from Johnson & Johnson and CTI BioPharma in the past week. Complete response letters were issued to Gilead Sciences, Amryt, and Reata Pharmaceuticals.